Adaptation and validation of the Treatment Burden Questionnaire (TBQ) in English using an internet platform

Viet-Thi Tran, Magdalena Harrington, Victor M Montori, Caroline Barnes, Paul Wicks, Philippe Ravaud, Viet-Thi Tran, Magdalena Harrington, Victor M Montori, Caroline Barnes, Paul Wicks, Philippe Ravaud

Abstract

Background: Treatment burden refers to the workload imposed by healthcare on patients, and the effect this has on quality of life. The Treatment Burden Questionnaire (TBQ) aims to assess treatment burden in different condition and treatment contexts. Here, we aimed to evaluate the validity and reliability of an English version of the TBQ, a scale that was originally developed in French.

Methods: The TBQ was translated into English by a forward-backward translation method. Wording and possible missing items were assessed during a pretest involving 200 patients with chronic conditions. Measurement properties of the instrument were assessed online with a patient network, using the PatientsLikeMe website. Dimensional structure of the questionnaire was assessed by factor analysis. Construct validity was assessed by associating TBQ global score wıth clinical variables, adherence to medication assessed by Morisky's Medication Adherence Scale (MMAS-8), quality of life (QOL) assessed by the PatientsLikeMe Quality of Life Scale (PLMQOL), and patients' confidence in their knowledge of their conditions and treatments. Reliability was determined by a test-retest method.

Results: In total, 610 patients with chronic conditions, mainly from the USA, UK, Canada, Australia, or New Zealand, completed the TBQ between September and October 2013. The English TBQ showed a unidimensional structure with Cronbach α of 0.90. The TBQ global score was negatively correlated with the PLMQOL score (rs = -0.50; p < 0.0001). Low rather than moderate or high adherence to medication was associated with high TBQ score (mean [SD] TBQ score 61.8 [30.5] vs. 37.7 [27.5]; P < 0.0001). The treatment burden was higher for patients who had insufficient knowledge compared with those who had sufficient knowledge about their treatments (mean ± SD TBQ score 62.3 ± 31.3 vs. 47.8 ± 30.4; P < 0.0001) and conditions (63.0 ± 31.6 vs. 49.3 ± 30.7; P < 0.0001). The intraclass correlation coefficient for the retest (n = 282) was 0.77 (95% CI 0.70 to 0.82).

Conclusions: We found that the English TBQ is a reliable instrument in this population, and provide evidence supporting the construct validity for its use to assess treatment burden for patients with one or more chronic conditions in English-speaking countries.

Figures

Figure 1
Figure 1
Bland and Altman plot of the test–retest reliability of the TBQ global score (n = 280).
Figure 2
Figure 2
Comparison of scores for TBQ items by country (n = 529)a.

References

    1. May C, Montori VM, Mair FS. We need minimally disruptive medicine. BMJ. 2009;339:b2803. doi: 10.1136/bmj.b2803.
    1. Eton DT, Ramalho de Oliveira D, Egginton JS, Ridgeway JL, Odell L, May CR, Montori VM. Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study. Patient Relat Outcome Meas. 2012;3:39–49.
    1. Eton DT, Elraiyah TA, Yost KJ, Ridgeway JL, Johnson A, Egginton JS, Mullan RJ, Murad MH, Erwin PJ, Montori VM. A systematic review of patient-reported measures of burden of treatment in three chronic diseases. Patient Relat Outcome Meas. 2013;4:7–20.
    1. Jowsey T, Yen L, PM W. Time spent on health related activities associated with chronic illness: a scoping literature review. BMC Public Health. 2012;12:1044. doi: 10.1186/1471-2458-12-1044.
    1. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294:716–724. doi: 10.1001/jama.294.6.716.
    1. Guthrie B, Payne K, Alderson P, McMurdo ME, Mercer SW. Adapting clinical guidelines to take account of multimorbidity. BMJ. 2012;345:e6341. doi: 10.1136/bmj.e6341.
    1. Montori VM, Brito JP, Murad MH. The optimal practice of evidence-based medicine: incorporating patient preferences in practice guidelines. JAMA. 2013;310:2503–2504. doi: 10.1001/jama.2013.281422.
    1. Bohlen K, Scoville E, Shippee ND, May CR, Montori VM. Overwhelmed patients: a videographic analysis of how patients with type 2 diabetes and clinicians articulate and address treatment burden during clinical encounters. Diabetes Care. 2012;35:47–49. doi: 10.2337/dc11-1082.
    1. Tran VT, Montori VM, Eton DT, Baruch D, Falissard B, Ravaud P. Development and description of measurement properties of an instrument to assess Treatment Burden among patients with multiple chronic conditions. BMC Med. 2012;10:68. doi: 10.1186/1741-7015-10-68.
    1. Eton DT, Oliveira DR, Egginton J, Mair FS, May C, Montori VM. Understanding the burden of treatment in patients with multiple chronic conditions: Evidence from exploratory interviews. Qual Life Res. 2010;19:ab. 1673.
    1. McKenna SP. Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science. BMC Med. 2011;9:86. doi: 10.1186/1741-7015-9-86.
    1. Acquadro C, Conway K, Hareendran A, Aaronson N. Literature review of methods to translate health-related quality of life questionnaires for use in multinational clinical trials. Value Health. 2008;11:509–521. doi: 10.1111/j.1524-4733.2007.00292.x.
    1. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976) 2000;25:3186–3191. doi: 10.1097/00007632-200012150-00014.
    1. Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health. 2005;8:94–104. doi: 10.1111/j.1524-4733.2005.04054.x.
    1. Gallacher K, May CR, Montori VM, Mair FS. Understanding patients’ experiences of treatment burden in chronic heart failure using normalization process theory. Ann Fam Med. 2011;9:235–243. doi: 10.1370/afm.1249.
    1. Gallacher K, Morrison D, Jani B, Macdonald S, May CR, Montori VM, Erwin PJ, Batty GD, Eton DT, Langhorne P, Mair FS. Uncovering treatment burden as a key concept for stroke care: a systematic review of qualitative research. PLoS Med. 2013;10:e1001473. doi: 10.1371/journal.pmed.1001473.
    1. Sav A, Kendall E, McMillan SS, Kelly F, Whitty JA, King MA, Wheeler AJ. ‘You say treatment, I say hard work’: treatment burden among people with chronic illness and their carers in Australia. Health Soc Care Community. 2013;21:665–674.
    1. The Open Research Exchange. [ ]
    1. Wicks P, Heywood B, Heywood J. Online platform to accelerate patient involvement in open instrument development. Qual Life Res. 2013;22:55.
    1. PatientsLikeMe. [ ]
    1. Cronbach L. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334. doi: 10.1007/BF02310555.
    1. Nunnaly J, Bernstein I. Psychometric theory. 3. New York: McGraw-Hill; 1994.
    1. Slawsky K, Massagli M, Wicks P. PRM30 a comparison of the PatientsLikeMe Quality of Life Questionnaire (PLMQOL) with the RAND SF-36. Value Health. 2011;14:A426.
    1. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J ClinHypertens (Greenwich) 2008;10:348–354. doi: 10.1111/j.1751-7176.2008.07572.x.
    1. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74. doi: 10.1097/00005650-198601000-00007.
    1. Diederichs C, Berger K, Bartels DB. The measurement of multiple chronic diseases–a systematic review on existing multimorbidity indices. J Gerontol A BiolSci Med Sci. 2011;66:301–311.
    1. Juniper E, Guyatt G, Jaeschke R. In: Quality of life and pharmacoeconomics in clinical trials. Spilker B, editor. Philadelphia - New York: Lippincott - Raven; 1996. How to develop and validate a new health-related quality of life instrument; pp. 49–56.
    1. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420–428.
    1. Streiner D, Norman G. Health Measurement Scales: a practical guide to their development and use, Fourth Edition edn. Oxford: Oxford University Press; 2008.
    1. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8:135–160. doi: 10.1191/096228099673819272.
    1. The R Project for Statistical Computing. [ ]
    1. Ubel PA, Abernethy AP, Zafar SY. Full disclosure–out-of-pocket costs as side effects. N Engl J Med. 2013;369:1484–1486. doi: 10.1056/NEJMp1306826.
    1. Ekman A, Litton JE. New times, new needs; e-epidemiology. Eur J Epidemiol. 2007;22:285–292. doi: 10.1007/s10654-007-9119-0.
    1. Bove R, Secor E, Healy BC, Musallam A, Vaughan T, Glanz BI, Greeke E, Weiner HL, Chitnis T, Wicks P, De Jager PL. Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One. 2013;8:e59707. doi: 10.1371/journal.pone.0059707.
    1. Wicks P, Sulham KA, Gnanasakthy A. Quality of life in organ transplant recipients participating in an online transplant community. Patient. 2014;7:73–84. doi: 10.1007/s40271-013-0033-0.
    1. De la Loge C, Keininger D, Isojärvi J, Massagli MP, Wicks P. 63rd Annual Meeting of the American Academy of Neurology. Honolulu, USA; 2011. Characteristics of users of the epilepsy community of and comparison with a representative claims database.
    1. Bowden A, Fox-Rushby JA. A systematic and critical review of the process of translation and adaptation of generic health-related quality of life measures in Africa, Asia, Eastern Europe, the Middle East, South America. Soc Sci Med. 2003;57:1289–1306. doi: 10.1016/S0277-9536(02)00503-8.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する